Best Fibroscan doctors: TOP 43 doctors

Membership in societies:

Expert of scientific journals 

Close co-operation with leading surgeons

Membership of the German Medical Association 

Specialities:

Introduction of new and modern techniques in the field of oncological surgery
General and visceral surgery

Minimally invasive surgery

Gastrointestinal oncology surgery

Oncological surgery

Haemorrhoids treatment

Additional clinical specialisation in minimally invasive and hernia surgery

Surgery and transplantation of the pancreas

Work Experience:

2005: Specialist in the field of surgery

2008: Appointed Senior Consultant specialising in pancreatic surgery and transplantation

2010: Coordinator of the Pancreatic Cancer Centre (Oncocert)

2013: Specialist in visceral surgery

2014: Managing Senior Physician, additional clinical specialisation in minimally invasive and hernia surgery

2019: Chief Surgeon of the Colorectal Cancer Centre Bochum (the first certified colorectal cancer centre in Germany and one of the first certified leading colorectal centres in Europe)

2021: Chief Surgeon of the Department of Surgery at the Academic Hospital Solingen

Thanks to the professor and his team, the department has been modernised by introducing modern surgical methods of treatment and especially improved methods of post-operative recovery. The Department of Surgery at the Solingen Clinic is now further expanding its focus on minimally invasive surgery in the direction of robotics. The clinic has allocated a huge budget for the purchase of state-of-the-art equipment in order to offer patients a full range of surgical methods for the treatment of benign and malignant diseases of the oesophagus, lungs, stomach, liver, pancreas and intestines according to current guidelines and using the most modern technical equipment.

Professor Schenker is an active researcher and lecturer. He lectures at medical universities and organises seminars and workshops for colleagues. He cooperates closely with the Cancer Centre, the Pancreatic Cancer Treatment Centre, the Intestinal Cancer Treatment Centre and the Interregional Trauma Centre.

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Dr. Omer Burcak Binicier is a gastroenterology specialist with strong medical training. He earned his medical degree at Ege University. He completed his internal medicine and gastroenterology specialization at Dokuz Eylül University Faculty of Medicine. Dr. Binicier has over ten years of clinical experience. He has held key positions at SBÜ Tepecik Training and Research Hospital and İzmir Bayraklı City Hospital. He also gained international experience at Korea University.

Dr. Binicier diagnoses and treats a wide range of gastrointestinal diseases. His expertise includes early colon and stomach cancers, inflammatory bowel diseases, liver and pancreatic disorders, and digestive system cancers. He uses advanced endoscopic techniques such as EMR, ESD, ERCP, and endoscopic ultrasound. He is also skilled in minimally invasive obesity treatments. His clinical skills are built on years of hands-on work in top medical centers.

Dr. Binnur Simsek is a gastroenterology specialist. She has experience in liver cirrhosis, portal hypertension, hepatocellular carcinoma, liver transplantation, and viral hepatitis (B, C, Delta). She also treats alcoholic and non-alcoholic fatty liver disease, peptic ulcers, gastrointestinal bleeding, and inflammatory bowel diseases such as ulcerative colitis and Crohn’s colitis.

She completed her medical and gastroenterology training at Istanbul University Faculty of Medicine. Dr. Simsek has worked at Istanbul University, Sanlıurfa Education and Research Hospital, Liv Hospital, and Istinye University. She is a member of the Turkish Association for the Study of the Liver and the Turkish Society of Gastroenterology.

Education

• (2004 – 2011), Faculty of Medicine/ Inonu University/ Malatya, Turkiye
• (2011 – 2015), Department of Radiology/ Bagcilar Training and Research Hospital/ Istanbul, Turkiye

Career

• (2016 – 2020), Diagnostic and Interventional Radiologist/ Mus State Hospital/ Mus,Turkiye
• (2020 – 2022), Assistant Professor of Diagnostic and Interventional Radiology/ Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2023 – 2024), Associate Professor of Diagnostic and Interventional Radiology /Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2024 - Present), Associate Professor of Diagnostic and Interventional Radiology /Medipol University Hospital/ Istanbul, Turkiye

Gastroenterology

Pendik Medipol University Hospital

Education

1999 Karadeniz Technical University, Gastroenterology

1997 Atatürk University, Internal Diseases Professorship

1992 Atatürk University, Internal Diseases Associated Professorship

1985 Atatürk University, Internal Diseases Specialist

1981 Atatürk University Faculty of Medicine

Publications

1- Nihat Okçu Gülçin Polat, Arif Yılmaz, Mehmet Koruk, The demographic features of gastric cancers in Erzurum(Eurasian J Med 2000; 32: 63-65)

2- An Evaluation of Upper Gastrointestinal Bleeding Cases. Clinical Sciences-Doctor.2000, - E.akarsu,N.Okçu,et Ark.Northeast Anatolia 6:4:435-438

3-N.Okçu, A.yılmaz. İ.kiki,MDonuk, C.gündoğdu, H.uzunismail. Our Diagnostic Upper Gastrointestinal Endoscopy Results. Atatürk University Medical Journal 1997,29 (2):486

4-N. Okçu, M.gündoğdu, MD onuk, İ.kiki, l.cerrahoğlu, k.yılmaz, I. çapoğlu. The Role of Misoprostol in Preventing Gastroduodenal Lesions in Patients Using Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Atatürk University Medical Journal 1997,29 (2):453-455.

5-N.Okçu, A. Öz, MD Onuk, E.Akarsu, B. Tekin, Hz Tonbul, H.Kaya. Plasma Fibronectin Levels in Chronic Active Hepatitis and Decoction of Liver Parenchymal Insufficiency and Their Relationship with Liver Functional Status. Turkish J. Gastroenterol 1995;27(4): 422-426.

6-N.Okçu, Tahir Buran, MD Onuk, A. Yılmaz, E.Akarsu, G. Akçay. Prevalence of Helicobacter Pylori in Patients with Duodenal Ulcer in Erzurum and Surrounding Area. Turkish J. Gastroenterol 1995;27(4): 447-450.

7-N.Okçu, bs awake, e. akarsu, e. bakan, z. tonbul. Importance of Carbohydrate Antigens (CA-19-9, CA-125), Carcinoembryonic Antigen (CEA) and Alkaline Phosphatase in Gastric and Colorectal Cancers. Turkish J. Gastroenterol 1995;6:467-471.

8-N. Okçu, MD Onuk, E. Akarsu, H. Doğan, C. Gündoğdu. Major Risk Factors in Patients with Hepatocellular Carcinoma in Our Region. Gastroenterology 1994;5(2):154-157

9-N.Okçu, md. Onuk, e. akarsu, h. doğan, c.gündoğdu, tahir buran. Frequency of gastric carcinoma in Erzurum region, endoscopic and histological features. Gastroenterology 1994;5(2):263-267.

10-N. Okçu, MD Onuk, Tahir Buran, E. Akarsu, MA Çiftçioğlu. Frequency of Helicobacter Pylori in Nonspecific Gastritis Cases in Erzurum Province. Gastroenterology 1994;5(2):211-213.

11-N.Okçu, MD Onuk, Ö. Ünal, E. Akarsu, L. İncesu, K. Akgöz. Diagnostic Value of Ultrasound-Guided Fine Needle Aspiration Biopsy in Intra-Abdominal Mass Lesions. Gastroenterology 1993;4(1):166-68.

12-NOkçu, md. onuk, m. polat, a. yılmaz, m. gündoğdu, m. paç. Budd-Chiari Syndrome (2 Cases). Turkish J Gastroenterhepatol 1993; 4(1):77-80.

13-N.Okçu, H. Koçak, MD Onuk, M. Gündoğdu, E. Bakan, A. Yılmaz, A. Başoğlu, A. Ateş, F.A. Paç. The Effect of Atrial Pressure Changes and Cardiac Nerves on Plasma Atrial Natriuretic Peptide (ANP) Levels. Vascular Surgery 1993; 27(2): 128-132

15-N.Okçu, MD Onuk, A.Yılmaz, M. Gündoğdu, T. Buran. Effects of Omeprozole and Ranitidine on Peptic Ulcer Healing. Doğa-Tr.J. of Medical Sciences 1992;16:657-658.

16-N. Okçu, Mr. Yiğitoğlu, B. Adam, E. Bakan. The Effect of Digixin on Plasma Atrial Natriuretic Peptic Level in Patients with Congestive Heart Failure. S.Ü. Medical Faculty Journal 1991;7(2):243-247..

17-N.Okçu, A. Yılmaz. The Effect of Histamine H2 -Receptor Antagonists in Upper Gastrointestinal System Bleeding. Endoscopy Journal 1991;2(4):17-23.

18-N.Okçu, E. Bakan, B. Adam, A. Yılmaz, Mr. Yiğitoğlu. Sex Hormones and Sex Hormone Binding Globulin Levels in Patients with Chronic Hepatitis and Liver Cirrhosis (Letter to the Editor). Nature-Tr. J. Of Medical Sciences 1991;15:1-2.

19-N.Okcu Ömer Yılmaz.Helıcobacter pylori and related gastrointestinal system diseases. Turkish Clinics JMed Sci. 2013;33(3):806-13

20-Nihat Okçu, Ömer Yılmaz, Hakan Dursun, Gülçin Polat. The relationship between dyspeptic symptoms, nutritional habits, endoscopic and histological findings (Eurasian J Med 2006; 38: 13-17)

21-Mehmet Bilici,1Nihat Okcu,1Kerim Cayir,1Ibrahim Pirim,2Salim B. Tekin,1andCemal Gundogdu3 - Distribution of HLA Tissue Groups in Patients with Gastric Cancer Eurasian J Med. 2010 Apr; 42(1): 9.11.

22-Nihat Okcu,Abdulhalim Bak,Mehmet Sari,Mehmet Arslan,Sait Kapicioglu:The fibroblast proliferation, relationship of hepatocyte growth factor (HGF) and interferon-A2A Gastroenterology April 2000Volume 118,Issue 4, Part 2, PageA1404

23-Kubra Kaynar,Sait Kapicioglu,Mehmet Sari,Nihat Okcu,Abdulhalim Baki. The effect of fish oil on stress ulcer prophylaxis GastroenterologyVolume 118, Issue 4, Part 2, PageA1255

Dr. Elnur Sahibov is a licensed Radiation Oncologist with 8 years of medical training and clinical experience. He completed his undergraduate and specialization studies at Marmara University Faculty of Medicine. From 2012 to 2016, he focused on advanced radiation oncology techniques.

Dr. Sahibov is known for his expertise in cancer treatment. He has helped improve patient outcomes and uses evidence-based protocols. He is accredited by leading medical institutions and is dedicated to ongoing professional development in oncology.

Dr. Raj Nagarkar is a leading Surgical Oncologist with 19 years of experience. He has performed over 50,000 cancer surgeries. His main focus areas are Breast and Thoracic Surgical Oncology. He is involved in more than 200 clinical trials and has contributed to many national and international publications.

Dr. Nagarkar trained in Surgical Oncology at Tata Memorial Hospital, Mumbai. He also holds an MRCS from the Royal College of Surgeons, Edinburgh. He teaches DNB Superspecialty Surgical Oncology and Breast Surgery at Maharashtra University of Health Sciences. Dr. Nagarkar is dedicated to improving the quality of life for his patients.

Dr. Kayihan Engin is a Radiation Oncologist. He earned his medical degree from Uludağ University Medical College in 1983. He completed his residency in Radiation Oncology at the Center of Oncology & Nuclear Medicine in Istanbul in 1990. From 1990 to 1994, he pursued a post-doctoral fellowship in Thermoradiotherapy at Thomas Jefferson University in the USA.

Dr. Engin has held key academic and leadership roles. He served as Professor, Chairman, and Faculty Accreditation Coordinator at Uludağ University Medical College from 1991 to 2005. He was also Professor and Director at Anadolu Medical Center between 2004 and 2017. Since 2017, he has led the Oncological Sciences departments at Ceylan International and Medicana Bursa Hospitals. Dr. Engin is known for his work in improving cancer treatment and medical education standards in Turkey.

Dr. Sridhar P.S. is a skilled radiation oncologist. He earned his Bachelor of Medicine from Mysore University. He completed his MD in Radiotherapy at Banaras Hindu University. He also holds a Diplomate of the National Board in Radiotherapy. This shows his advanced training and dedication to quality care.

Dr. Sridhar is a member of several professional groups. These include the Association of Radiation Oncology of India, Society for Neuro-Oncology, Bangalore Oncology Group, and the Indian Association of Hyperthermia Oncology. He is known for his effective cancer treatments and focus on new therapies. His work has made a positive impact in the field of oncology.

Dr. Chaitainya Borde is a nuclear medicine specialist with 12 years of clinical experience. He is skilled in advanced nuclear scans, PET-CT imaging, and nuclear cardiology. He works in both diagnostic and therapeutic nuclear medicine.

Dr. Borde has performed over 30,000 PET scans. He has managed more than 1,000 thyroid cancer patients. He is experienced in radioiodine and Lu-177 RN therapies. He has also published research papers in respected medical journals, showing his dedication to academic work.

Dr. Shruti Kate is an experienced oncologist. She specializes in treating lung, breast, gynecological, and genitourinary cancers. She earned her MBBS from Lady Hardinge Medical College. She completed her MD in Internal Medicine at Maulana Azad Medical College. She also holds a DM in Medical Oncology from Tata Memorial Hospital, Mumbai.

Dr. Kate has managed both conservative and surgical cancer treatments. She is skilled in complex procedures such as the Whipple surgery. She is a member of several leading oncology societies, including ASCO, ESMO, IASCLC, ISMPO, and IOS. Her research on lung cancer received the only travel award from India at the 2018 World Conference on Lung Cancer.

Dr. Ahmer Arif Shaikh, MDS (Oral & Maxillofacial Surgery), is a specialist in Surgical Oncology. He has 3 years of experience at HCG Manavata Cancer Centre, Nashik. He focuses on oral cancer treatment, organ preservation, and functional rehabilitation for oral cancer patients.

Dr. Shaikh has completed a Fellowship in Head & Neck Surgical Oncology. He is skilled in complex maxillofacial and head & neck surgeries. He is also an active researcher with several publications in reputed journals. His work shows a strong commitment to improving cancer care.

Dr. Lalit Banswal is an experienced oncological surgeon with 10 years in the field. He has performed more than 10,000 major surgeries. He earned his MBBS from MIMER, Pune, and completed his MS at GMC Panaji. He also completed a fellowship in Surgical Oncology at Tata Medical Centre, Kolkata, with a focus on gastrointestinal cancers.

Dr. Banswal has worked as a Co-principal Investigator in several research projects. He has published his work in both national and international journals. He is known for his patient-friendly and ethical approach. His main expertise is in Minimal Invasive Cancer Surgeries, where he consistently delivers excellent results.